Individual results vary, and NexLife does not guarantee weight loss, treatment success, clinical outcomes, prescription approval, medication eligibility, pharmacy availability, fulfillment timelines, or delivery outcomes
This is the shared pathway across all three compounds
Here are the medications that contain liraglutide: Saxenda , a daily injection approved for weight management Victoza , a daily injection approved for type 2 diabetes and cardiovascular risk reduction Generic liraglutide , a daily injection approved for weight loss, type 2 diabetes, and cardiovascular risk
Secondary outcomes included absolute change in body weight and weight circumference from 36 to 88 weeks, the percentage of adults achieving at least a 5%, 10%, 15%, 20% or 25% weight loss from baseline to 88 weeks and the percentage of adults that maintained at least 80% of the body weight they lost during the open-label period